Status:
UNKNOWN
Gut Permeability-related Inflammation and Cardiovascular Disease Risk in Normal-weight and Metabolically Healthy Obesity
Lead Sponsor:
Oklahoma State University
Conditions:
Obesity
Eligibility:
All Genders
18-50 years
Brief Summary
The investigators are examining the extent gut permeability explains observed inflammation in normal-weight and metabolically healthy obesity (and potentially cardiovascular disease risk).
Detailed Description
Cardiovascular disease (CVD) is responsible for 25% of deaths in the United States, and chronic inflammation contributes to risk. A growing body of evidence suggests that gut-derived bacterial compone...
Eligibility Criteria
Inclusion
- Control group: normal BMI, body fat percentage \< 25% for men and \< 35% for women, \< 1 of the following: blood pressure \>130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, HDL cholesterol \< 40 mg/dL (men) or \< 50 mg/dL (women).
- Normal-weight obesity group: normal BMI, body fat percentage \> 25% for men and \> 35% for women.
- Metabolically healthy obesity: BMI \> 30, body fat percentage \> 25% for men and \> 35% for women, and \< 1 of the following: blood pressure \>130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, HDL cholesterol \< 40 mg/dL (men) or \< 50 mg/dL (women).
- Metabolic syndrome group: BMI \> 30, body fat percentage \> 25% for men and \> 35% for women, and 2 or more of the following: blood pressure \>130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, HDL cholesterol \< 40 mg/dL (men) or \< 50 mg/dL (women).
Exclusion
- Presence of pacemaker
- Pregnant
- Cardiometabolic disease (e.g., diabetes, cardiovascular disease)
- Disease that is inflammatory in nature (e.g., inflammatory bowel disease, rheumatoid arthritis)
- Postmenopausal status
- Use of tobacco products
- Using illicit drugs
- Using lipid lowering drugs
Key Trial Info
Start Date :
March 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05308394
Start Date
March 10 2022
End Date
December 30 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
208 Nancy Randolph Davis, Oklahoma State University
Stillwater, Oklahoma, United States, 74078